CureVac N.V. (NASDAQ:CVAC) Q3 2023 Earnings Call Transcript

Charlie Yang: If I can just ask one clarifying question over there. So the two programs we’re seeing right now is the intention of moving those programs into CAL pivotal trial? Or are they more of a proof-of-concept programs?

Alexander Zehnder : So maybe I can step in. So you’re referring to the oncology program, right, the GBM current ongoing trial, right? It’s more like a proof-of-concept trial. So I would say, unless we see overwhelming efficacy because this is kind of a construct with known antigens that are relevant for — but we believe in our FramePro platform, as Myriam mentioned, we will be able to have a much more comprehensive approach to antigens and picking the right antigens, right? So we’re going to focus on that second generation, let’s say, based on our proprietary research coming from the Frame Cancer Therapeutics acquisition. And that’s what we’re working on and moving these programs to the clinic of the shelf. And as Myriam has mentioned, we are working on the personalized cancer vaccines as well.

Charlie Yang: I see. So the CV8102, that’s also a proof-of-concept program, but the main focus for you guys will be on the new antigen one that those are kind of in the — still in the preclinical development phase, is that how I should think about it?

Myriam Mendila: Yes. This is Myriam. Sorry, I was kicked out of the call, I’m back. Yes, you’re absolutely right. Our focus will be basically using the new antigens that we — that came out of our own discovery work and because we do believe that we have a very sophisticated approach to select signals antigens. So first to discover them, but also to select them to predict the immunogenicity and hence, that’s basically the way we want to go forward.

Charlie Yang: Great. Thanks so much

Operator: Thank you. There are no further questions at this time. And I would like to turn the floor back over to Sarah Fakih for closing comments.

Sarah Fakih : Thank you. With this, we would like to conclude this conference call. Thank you very much for your participation. Stay safe, and please don’t hesitate to contact us should you have any further questions. Thank you, and goodbye.